Free tool
FAERS Monitor: Simlandi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761299 or its brand name (Simlandi, Adalimumab-Ryvk). Reports on generic versions are filed under their own applications.
Reports
1,090
Serious
876
80% of reports
Hospitalization
276
Death reported
78
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use149
- product dose omission issue135
- crohn^s disease127
- pain103
- drug ineffective99
- inappropriate schedule of product administration99
- rheumatoid arthritis91
- arthralgia87
- fatigue87
- diarrhoea81
- death74
- headache68
- abdominal pain63
- hospitalisation50
- malaise50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 245 |
| 2025 | 358 |
| 2026 | 481 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,069 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 91 | 15.5 | 12.7 | 1,224 |
| inappropriate schedule of product administrationSignal | 99 | 10.6 | 8.8 | 859 |
| product dose omission issueSignal | 135 | 8.9 | 7.6 | 947 |
| hospitalisationSignal | 50 | 6.3 | 4.8 | 218 |
| abdominal painSignal | 63 | 5.2 | 4.1 | 213 |
| arthralgiaSignal | 87 | 4.0 | 3.3 | 200 |
| off label useSignal | 149 | 3.3 | 2.8 | 245 |
| painSignal | 103 | 3.2 | 2.7 | 162 |
| diarrhoeaSignal | 81 | 2.4 | 2.0 | 68 |
| malaiseSignal | 50 | 2.2 | 1.7 | 32 |
| fatigueSignal | 87 | 2.2 | 1.8 | 55 |
| headacheSignal | 68 | 2.1 | 1.7 | 39 |
| death | 74 | 1.7 | 1.3 | 19 |
| drug ineffective | 99 | 1.4 | 1.2 | 14 |
| crohn^s disease | 127 | 0.0 | 0.0 | 2,433,709 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.